STOCK TITAN

SCWorx (NASDAQ: WORX) wins conditional Nasdaq panel listing reprieve

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

SCWorx Corp. received a decision from a Nasdaq Hearings Panel allowing its common stock to continue listing on Nasdaq, subject to strict compliance conditions. Trading had been suspended after the stock failed to meet the Nasdaq minimum bid price of $1.00 per share.

To regain trading on Nasdaq, SCWorx must obtain shareholder approval for a reverse stock split by July 22, 2026, implement the reverse split by August 3, 2026, and then demonstrate a closing bid of at least $1.00 per share for 20 consecutive trading days by August 28, 2026. If it fails, the stock would remain quoted on OTC Markets, where it has approval for quotation on the OTCQB Market.

Positive

  • None.

Negative

  • None.

Insights

SCWorx receives a conditional Nasdaq listing reprieve tied to a reverse split and bid-price milestones.

SCWorx has avoided immediate Nasdaq delisting through a Hearings Panel decision that grants continued listing only if it executes a reverse stock split and restores compliance with the $1.00 minimum bid price requirement. This shifts the near-term focus to corporate actions rather than operations.

The conditions are tightly sequenced: shareholder approval for a reverse split by July 22, 2026, execution by August 3, 2026, and at least 20 consecutive trading days with a bid at or above $1.00 by August 28, 2026. The Panel and the Nasdaq Listing and Hearing Review Council each retain authority to alter or overturn this outcome.

Until any Nasdaq trading reinstatement, the shares have approval to be quoted on the OTCQB Market, which may have lower liquidity. Future company communications, including updates on the reverse split vote and post-split trading performance, will clarify whether these listing conditions are ultimately met.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Minimum bid price requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) Bid Price Rule
Shareholder approval deadline July 22, 2026 Deadline to obtain approval for reverse stock split
Reverse split implementation deadline August 3, 2026 Date by which SCWorx must effect reverse stock split
Bid-price compliance deadline August 28, 2026 Deadline to show $1.00 bid for 20 consecutive days
Required trading streak 20 trading days Consecutive days with bid at or above $1.00
Review window 45 calendar days Period for Nasdaq Listing and Hearing Review Council review
reverse stock split financial
"obtain shareholder approval for a reverse stock split at a ratio sufficient"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Bid Price Rule regulatory
"maintain a minimum closing bid price of $1.00 per share (the “Bid Price Rule”)"
Nasdaq Hearings Panel regulatory
"received a written decision from a Hearings Panel of The Nasdaq Stock Market"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
OTCQB Market market
"approval from OTC Markets to have its common stock quoted on the OTCQB Market"
The OTCQB Market is a regulated tier of the over‑the‑counter (OTC) trading system where smaller or early‑stage stocks trade with modest reporting and quality standards. Think of it as a neighborhood market that sits between an informal garage sale and a big supermarket: it offers more information and oversight than the lowest OTC tier, but less liquidity and scrutiny than major exchanges. Investors care because it signals a middle level of transparency and risk, affecting how easy shares are to buy, sell and evaluate.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the federal securities laws."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Nasdaq Listing and Hearing Review Council regulatory
"the Nasdaq Listing and Hearing Review Council may, on its own motion, determine to review the Decision"
A Nasdaq Listing and Hearing Review Council is an independent appeal panel that examines contested decisions about a company’s eligibility to be listed or removed from the Nasdaq stock market. Think of it as a referee review for listing rulings: it gives companies a second look and investors transparency around whether a stock stays tradable on that exchange, which can affect a company’s visibility, liquidity, and investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001674227 0001674227 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 17, 2026

 

SCWorx Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37899   47-5412331
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

35 Village Rd, Suite 100

Middleton, MA 01949

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (844) 472-9679

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 8.01. Other Events.

 

On June 17, 2026, SCWorx Corp. (the “Company”) received a written decision (the “Decision”) from a Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request to continue the listing of its common stock on Nasdaq, subject to the conditions described below.

 

As previously disclosed, trading in the Company’s common stock was suspended on April 14, 2026 as a result of the Company’s failure to satisfy the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), which requires that the Company maintain a minimum closing bid price of $1.00 per share (the “Bid Price Rule”). The Company appealed the Staff’s delisting determination to the Panel, and the Decision resolves that appeal.

 

Under the terms of the Decision, the Company must satisfy the following conditions in order for trading of its common stock to be reinstated on Nasdaq: (i) on or before July 22, 2026, the Company must obtain shareholder approval for a reverse stock split at a ratio sufficient to achieve a post-split price reasonably expected to sustain compliance with the Bid Price Rule; (ii) on or before August 3, 2026, the Company must effect a reverse stock split; and (iii) on or before August 28, 2026, the Company must demonstrate compliance with the Bid Price Rule by evidencing a closing bid price at or above $1.00 per share for a minimum of 20 consecutive trading days.

 

If the Company does not satisfy these conditions by the applicable deadlines, its common stock would be delisted from Nasdaq and trading on Nasdaq would not be reinstated, in which case the common stock would continue to be quoted on the OTC Markets, subject to compliance with applicable OTC Markets rules. The Panel reserved the right to reconsider the terms of the exception it granted, should any developments arise that, in the Panel’s judgment, make continued listing of the Company’s securities inadvisable or unwarranted. In addition, under applicable Nasdaq rules, the Nasdaq Listing and Hearing Review Council may, on its own motion, determine to review the Decision within 45 calendar days after its issuance, and upon any such review may affirm, modify, reverse, dismiss or remand the Decision.

 

In connection with the suspension of trading on Nasdaq, the Company has received approval from OTC Markets to have its common stock quoted on the OTCQB Market.

 

On June 23, 2026, the Company issued a press release announcing the Decision. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release issued by SCWorx Corp. on June 23, 2026 (furnished, not filed).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 23, 2026

 

  SCWorx Corp.
   
  By: /s/ Timothy A. Hannibal
  Name:  Timothy A. Hannibal
  Title: Chief Executive Officer

 

2

Exhibit 99.1

 

SCWorx Receives Nasdaq Hearings Panel Decision Granting the Company’s Request to Continue its Listing on the Nasdaq Stock Market, Subject to Compliance Conditions

 

MIDDLETON, MA, June 23, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (“SCWorx” or the “Company”), a provider of data normalization and supply chain solutions for the healthcare industry, today announced that it has received a decision from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to satisfaction of certain conditions. By way of background, trading in the Company’s common stock was suspended on April 14, 2026 because the Company failed to meet the requirements of Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”).

 

Under the terms of the Panel’s decision, SCWorx must comply with the following conditions, in order for trading of its common stock to be reinstated on Nasdaq: (i) on or before July 22, 2026, we must obtain shareholder approval for a reverse stock split, at a ratio sufficient to achieve a post-split price reasonably expected to sustain compliance with the Bid Price Rule; (ii) on or before August 3, 2026, we must effect a reverse stock split; and (iii) on or before August 28, 2026, we must demonstrate compliance with the Bid Price Rule by evidencing a closing bid price at or above $1.00 per share for a minimum of 20 consecutive trading days.

 

If the Company does not satisfy the Panel’s conditions by the applicable deadlines, its common stock would be delisted from Nasdaq and trading on Nasdaq would not be reinstated, in which case its common stock would continue to be quoted on OTC Markets, subject to compliance with applicable OTC Market rules.

 

The Panel reserved the right to reconsider the terms of the exception it granted the Company, should any developments arise that, in the Panel’s judgment, make continued listing of the Company’s securities inadvisable or unwarranted.

 

Under applicable Nasdaq Rules, the Nasdaq Listing and Hearing Review Council may, on its own motion, determine to review any Panel decision within 45 calendar days after issuance of the written decision. If the Listing Council determines to review the Panel Decision, it may affirm, modify, reverse, dismiss or remand the decision to the Panel.

 

“We appreciate the Panel’s consideration and the opportunity to continue our Nasdaq listing while we execute our compliance plan,” said Tim Hannibal, President and Chief Executive Officer of SCWorx. “Maintaining our Nasdaq listing remains a strategic priority as we continue to focus on expanding customer and partner relationships, advancing our healthcare supply chain data management platform, including through the use of artificial intelligence, and creating long-term value for shareholders.”

 

 

 

The Company intends to take all actions necessary to satisfy the conditions established by the Panel and will continue to keep investors informed regarding its progress.

 

Pending potential reinstatement of trading, which is subject to satisfaction of the Panel’s compliance conditions, the Company has received approval from OTC Markets to have its common stock quoted on the OTCQB Market.

 

About SCWorx Corp.

 

SCWorx has created and markets solutions that improve the accuracy, interoperability and utilization of information within healthcare provider organizations. SCWorx’s solutions enable healthcare organizations to simplify data management, improve supply chain performance, support ERP implementations, and drive operational efficiencies through advanced data normalization and analytics.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to, statements regarding the Company’s ability to achieve or sustain the $1.00 bid price (particularly given the illiquidity of the OTC Markets), meet the deadlines imposed by the Nasdaq Hearings Panel, satisfy the other conditions imposed by the Nasdaq Hearings Panel, maintain its Nasdaq listing, execute its business strategy, and achieve future growth. Actual results may differ materially from those projected in such forward-looking statements due to various risks and uncertainties. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission for a discussion of these and other risk factors. The Company undertakes no obligation to update any forward-looking statements except as required by law.

 

Investor Relations Contact:

 

SCWorx Investor Relations

ir@scworx.com

 

 

FAQ

What Nasdaq decision did SCWorx (WORX) announce in this 8-K?

SCWorx announced that a Nasdaq Hearings Panel granted its request to continue listing on The Nasdaq Stock Market, subject to meeting specific conditions tied to a reverse stock split and restoring compliance with the $1.00 minimum bid price rule.

What conditions must SCWorx (WORX) meet to reinstate Nasdaq trading?

SCWorx must secure shareholder approval for a reverse stock split by July 22, 2026, implement the split by August 3, 2026, and then show a closing bid of at least $1.00 per share for 20 consecutive trading days by August 28, 2026.

What happens if SCWorx (WORX) fails to meet the Nasdaq Panel conditions?

If SCWorx does not meet the deadlines or bid-price requirement, its common stock would be delisted from Nasdaq and trading would not be reinstated there, although the shares would continue to be quoted on OTC Markets, subject to applicable OTC Markets rules.

Where are SCWorx (WORX) shares quoted while Nasdaq trading is suspended?

While Nasdaq trading is suspended, SCWorx has received approval for its common stock to be quoted on the OTCQB Market operated by OTC Markets, providing an alternative trading venue as the company works to satisfy the Nasdaq Panel’s compliance conditions.

Can the Nasdaq Listing and Hearing Review Council change the SCWorx decision?

Yes. Under Nasdaq rules, the Nasdaq Listing and Hearing Review Council may, on its own motion, review the Panel’s written decision within 45 calendar days and may affirm, modify, reverse, dismiss, or remand that decision after its review.

What business does SCWorx (WORX) operate while addressing its listing issues?

SCWorx provides data normalization and supply chain solutions for healthcare providers. Its platform aims to improve data accuracy, interoperability, and utilization, supporting ERP implementations, enhancing supply chain performance, and driving operational efficiencies through advanced data normalization and analytics.

Filing Exhibits & Attachments

4 documents